BMS transfers Japan pemirolast rights
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibbhas agreed to divest Japanese manufacturing and marketing rights to the anti-allergic Pemilaston (pemirolast) to the domestic firm Alfresa Pharma. The two companies will begin joint promotional activities this month and the full transfer is due for completion next March. The change reflects a shift by BMS to other areas such as oncology, HIV and rheumatoid arthritis and an effort by Alfresa Pharma (part of the Alfresa pharmaceutical wholesaling group) to expand its existing allergy portfolio, the firms explained. Pemilaston is marketed in Japan in several adult and paediatric oral formulations and in ophthalmic form, for bronchial asthma, allergic rhinitis and conjunctivitis.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Merck & Co progresses cardiovascular strategy; Novo purchase builds heart failure presence; CRL setbacks for Regeneron; ITF faces challenging Duchenne field; and AbbVie needs to freshen up.